WebFeb 8, 2016 · There’s a new ETF in the market that sets out to reinvent biotech investing, one theme at a time. The Loncar Cancer Immunotherapy ETF (CNCR) is the first ETF to cover cancer treatment ... WebOct 16, 2015 · The Loncar Cancer Immunotherapy ETF (NasdaqGM: NASDAQ:CNCR) began trading Wednesday, October 14, according to a press release. CNCR has a 0.79% expense ratio. CNCR has a 0.79% expense ratio.
Loncar Cancer Immunotherapy ETF (CNCR) - Yahoo Finance
WebFind the latest Loncar Cancer Immunotherapy ETF (CNCR) stock quote, history, news and other vital information to help you with your stock trading and investing. WebThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar. Read More. redshirt ordnance
Cancer ETF Redefines Biotech Investing ETF.com
WebLearn everything about Loncar Cancer Immunotherapy ETF (CNCR). Free ratings, analyses, holdings, benchmarks, quotes, and news. (CNCR) Loncar Cancer … WebView Top Holdings and Key Holding Information for Loncar Cancer Immunotherapy ETF (CNCR). WebJun 3, 2024 · Loncar Cancer Immunotherapy ETF (CNCR): ETF Research Reports Celgene Corporation (CELG) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report ric keaster